

Figure 2. Etiology of liver transplantation (N=39)

<https://doi.org/10.1016/j.aohep.2024.101421>

N-acetyl cysteine prevents alterations generated during experimental liver steatosis induced by a chronic consumption of alcohol plus a hypercaloric diet.

Marina Galicia-Moreno, Katia B. Roa-Romero, Ángel O. Vázquez-Esqueda, Hugo C. Monroy-Ramírez, Rebeca Rosas-Campos, Ana S. Sandoval-Rodríguez, Juan Armendáriz-Borunda

Instituto de Biología Molecular en Medicina y Terapia Génica, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara

Introduction and Objectives: Metabolic alterations and alcohol consumption are the most common etiological agents related to hepatic steatosis (HS) development. There is little evidence that shows the effects generated by synergy of both etiologic agents. N-acetyl cysteine (NAC) is a drug whose efficacy in the early stages of SH, generated by a hypercaloric diet plus alcohol consumption, is unknown.

The aim of this work was to evaluate NAC effects on oxidative stress, and metabolic alterations induced in HS experimentally induced by chronic ethanol consumption plus a hypercaloric diet.

Materials and Patients: C57BL/6J mice (n=4) grouped into 1) Control; 2) HF/OH, administrated with hypercaloric diet and ethanol; 3) HF/OH+NAC, same treatments of group 2 plus NAC. Serum markers of liver damage and anorexigenic and orexigenic adipokines were evaluated; oxidative stress markers in liver samples were analyzed; finally, a H&E stain was performed. This project was conducted in accordance with the guidelines of the University of Guadalajara under the approval number of the bioethics, research, and ethics research committees CI-02920.

Results: NAC prevents weight gain and metabolic alterations generated by concomitant consumption of a hypercaloric diet and alcohol; this drug improves changes in anorexigenic and orexigenic adipokines such as leptin, ghrelin, resistin, GLP-1, and modulates total, HDL, and LDL cholesterol levels. On the other hand, NAC reduces CYP2E1 and alcohol dehydrogenase expression, as well as the oxidative environment induced by both etiologic agents, by avoiding an increase in malondialdehyde levels, promoting Nrf2 transcription factor expression and superoxide dismutase; also preventing an increase in the expression of Catalase. Finally, H&E staining showed that NAC prevents the development of tissue alterations in

the liver parenchyma generated by the consumption of a hypocaloric diet plus alcohol.

Conclusions: In this work, we demonstrate that NAC prevents metabolic alterations and oxidative damage related to early phases of HS induced by concomitant consumption of alcohol plus a hypercaloric diet. These effects would slow down the development of more severe stages of this disease.

Ethical statement

The study was conducted according to the guidelines of the Institutional Animal Care and Use Committee of UPAE-Bioterio at CUCS, University of Guadalajara (CI-02920).

Declaration of interests

None

Funding

This research was funded by Programa de Impulso a la Investigación-2021-II (PIN-2021-II) to M. G.-M

<https://doi.org/10.1016/j.aohep.2024.101422>

Hepatology at the Civil Hospital of Guadalajara, Fray Antonio Alcalde (HCGFAA) in the last 25 years and its international scientific productivity

Irene M. Mariscal-Martinez^{1,2}, Sonia Roman^{1,2}, Arturo Panduro^{1,2}

¹ Department of Genomic Medicine in Hepatology, Civil Hospital of Guadalajara "Fray Antonio Alcalde"; Guadalajara, Jalisco, Mexico

² Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, Mexico

Introduction and Objectives: With the creation of the Doctorate Program in Molecular Biology in Medicine, the first clinical and molecular hepatology research studies began at the HCGFAA in 1998. SCOPUS uses the H-Index to assess researchers' quality and scientific productivity; however, this parameter does not evaluate co-authorship, first author, or corresponding author. This bibliometric study aimed to evaluate the scientific productivity of the Department of Genomic Medicine in Hepatology-HCGFAA (Jalisco) and its current ranking in Mexico.

Materials and methods: We searched the CONAHCYT database and selected the active hepatology researchers according to the platform's classification categories (July 2022). Subsequently, we recollected SCOPUS's H-Index and estimated the co-author's number (collaboration index) per article, first author and corresponding author.

Results: We identified 31 hepatology researchers in the National Researchers' System (SNI): 18 level I, 5 level II, and 7 level III categories. A 78% of them are located in: Mexico City (13), Jalisco (7), and Nuevo Leon (4). The average number of scientific publications/H-Index was 20/7.6 in the SNI researchers' level I, SNI II 24/9.4, and SNI III 142/31. A 29% of SNI I researchers' publications belonged to the first author and corresponding author articles, SNI II had 36%, and SNI III had 43%. The maximum number of authors per article ranged from 3 to 1055. The average of international citations in the SNI I category was 271, SNI II 619, and SNI III 3566.

Conclusions: The data shows a consolidation of hepatology at HCGFAA in Jalisco, as well as in Mexico City and Nuevo Leon. The bibliometric parameters allowed us to evaluate the researcher's contribution as the first or corresponding author. It also revealed that cases with many co-authorships and highly cited articles in first-quartile journals are related to the consensus, pharmaceutical industry, and epidemiological studies.

Ethical statement

This study did not involve any patients or animal models and did not require approval.

Declaration of interests

None

Funding

U. de G. Programa de Fortalecimiento.

<https://doi.org/10.1016/j.aohep.2024.101423>

Prevalence of pregnancy liver diseases in patients at National Medical Center “La Raza” IMSS.

Areli Torres-Castro, Melissa Soto-Villalpando, Christopher J. Toranzo-González, Javier I. Carrillo-Rojas, Sarahi Ontiveros-Lopez, Iván A. Borunda-Saenz, Carlos M. Del Real-Calzada, María T. Rizo-Robles

UMAE Hospital of Specialties “Dr. Antonio Fraga Mouret” CMN “La Raza” IMSS

Introduction and Objectives: There are physiological changes in the hepatobiliary system during pregnancy. However, there are also pregnancy-related liver diseases, which occur in up to 3% of all pregnancies and can have potentially serious consequences for the mother and fetus. The most frequent are hyperemesis gravidarum, preeclampsia/eclampsia, elevated liver enzymes and low platelet count syndrome (HELLP), intrahepatic cholestasis of pregnancy (ICP) and acute fatty liver of pregnancy (AFLP). The prognosis depends on timely diagnosis and treatment. This study aimed to report the epidemiological characteristics of liver diseases in a Mexican population of pregnant women.

Materials and Patients: A retrospective descriptive observational study that included information collected from the electronic file of pregnant patients treated at UMAE HGO No. 3, of CMN La Raza, assessed by the Gastroenterology service of HE CMN “La Raza” in the period March 2021- May 2023.

Results: 142 patients were included, the mean age was 30 years, 54% were multiparous women, 8.4% of the patients were in the first trimester, 27% in the second trimester and 64% in the third trimester. In our total sample, alterations in liver biochemistry that met clinical and biochemical criteria for pregnancy-associated liver disease were analyzed, where 49% reported hypertransaminasaemia due to etiologies such as preeclampsia, HELLP syndrome, metabolic dysfunction associated fatty liver disease (MAFLD) and biliary pathology, 41% met criteria for ICP, 6% hyperemesis gravidarum, 1.4% were diagnosed with portal hypertension and liver cirrhosis, only 0.7% were diagnosed with autoimmune hepatitis and AFLP.

Conclusions: Based on solicited assessments over a 2-year period of women at any stage of pregnancy, hospitalized due to changes in liver biochemistry, most changes occurred in the third trimester of pregnancy, the most frequent disorder was intrahepatic cholestasis of the pregnancy, the rest of the pathologies were included in the hypertransaminasaemia group, where the most frequent causes were: MAFLD and cholelithiasis, less frequently: preeclampsia, HELLP syndrome or intrahepatic bile duct disorders.

Ethical statement

The protocol was registered and approved by the Ethics Committee. The identity of the patients is protected. Consentment was obtained.

Declaration of interests

None

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.




Figure 1. Prevalence of diagnoses.




Figure 2. Frequency of diagnoses according to trimester.

<https://doi.org/10.1016/j.aohep.2024.101424>

Regulation of TGF- β 1, 2, and 3 and IL-10 at systemic level in chronic liver disease

Marisela Hernandez-Santillan¹,
Abigail Hernandez-Barragan¹,
Moises Martínez-Castillo¹, Zaira Medina-Ávila¹,
Harumi Reséndiz-García¹, Erik Robledo-Ramírez¹,
Yadira Guizar-Alcántara¹, Amanda Álvarez-Rodea¹,
Danna Mercado-Herrera¹,
María F. Higuera-De La Tijera²,
José L. Pérez-Hernández², Daniel Santana-Vargas¹,
Gabriela Gutiérrez-Reyes¹

¹ Laboratorio de Hígado, Páncreas y Motilidad (HIPAM), Unidad de Investigación en Medicina Experimental, Facultad de Medicina, UNAM

² Servicio de Gastroenterología, Hospital General de México, Dr. Eduardo Liceaga

Introduction and Objectives: Chronic liver disease (CLD) is considered an important health problem worldwide. The production of IL-10 regulated the hepatic inflammation. Whereas TGF- β plays a crucial role during the progression of CLD, promoting the dysregulated production of extracellular matrix in the liver. However, the role of TGF- β 1, 2, and 3 and IL-10 in CLD is not completely understood. To evaluate the circulatory values of TGF- β 1, 2, and 3 and IL-10 in hepatitis C virus (HCV), Non-alcoholic fatty liver disease (NAFLD) and alcoholic cirrhosis (OHCi) and control subjects (CT).

Materials and Patients: A prospective, cross sectional, observational and multicentric study. HCV (n=33), NAFLD (n=33) and OHCi patients (n=22) and CT (n=26) were enrolled. The anthropometric variables, detailed clinical history and biochemical parameters were